New analysis shows fingolimod delays progression of MS disability
April 29th 2011Fingolimod (Gilenya, Novartis) reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history, according to a phase 3, 2-year study reported at the 63rd annual meeting of the American Academy of Neurology.
Read More
Dalteparin not better than unfractionated heparin for preventing DVT
April 29th 2011Dalteparin was not better than unfractionated heparin for the prevention of deep vein thrombosis among critically ill patients, according to an international study published in the New England Journal of Medicine.
Read More
White House, FDA act to reduce opioid misuse and abuse
April 29th 2011The Obama administration recently unveiled a multiagency plan to reduce the ?epidemic? of prescription drug abuse in the United States. It will include an FDA-backed education program that zeros-in on reducing the misuse and misprescribing of opioids.
Read More
Transdermal buprenorphine effective for moderate-to-severe chronic low back pain
April 22nd 2011Transdermal buprenorphine (Butrans Transdermal System, Purdue Pharma) was superior to placebo in treating opioid-naïve patients with moderate-to-severe chronic low back pain, according to study results presented at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.
Read More
Capsaicin patch reduces neuropathic pain of HIV-associated neuropathy
April 22nd 2011One 30-minute application of a capsaicin (8%) patch (NGX-4010, Qutenza, NeurogesX) can reduce neuropathic pain due to HIV-associated neuropathy, according to data presented here at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.
Read More
Successful switch to transdermal buprenorphine for OA pain of the hip, knee
April 22nd 2011Conversion to a 7-day regimen of transdermal buprenorphine (Butrans Transdermal System, Purdue Pharma) from a stable regimen of hydrocodone/acetaminophen (Vicodin, Abbott) can be successful in patients with osteoarthritic pain of the hip or knee, according to a study presented at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.
Read More
Topical diclofenac beats oral formulation in safety, tolerability
April 22nd 2011Topical diclofenac is safer and better tolerated by patients with osteoarthritis of the knee compared with the oral formulation, according to data presented here at annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.
Read More
FDA approves rituximab to treat rare disorders
April 20th 2011FDA has approved rituximab (Rituxan, Genentech) in combination with glucocorticosteroids for the treatment of 2 forms of anti-neutrophil cytoplasmic antibody-associated vasculitis, Wegener's granulomatosis and microscopic polyangiitis.
Read More
Vaginal progesterone gel reduces rate of preterm birth
April 15th 2011The administration of vaginal progesterone from the mid-trimester of pregnancy until term in women with a premature cervical shortening as confirmed by transvaginal ultrasound significantly reduced the rate of preterm birth before 33 weeks gestation, according to a phase 3 study published online April 6 in Ultrasound in Obstetrics & Gynecology.
Read More
AHA presents guidelines for managing manifestations of VTE
April 15th 2011There are several advanced therapies in addition to blood thinners that physicians should consider when managing patients with deep vein thrombosis, according to a new scientific statement from the American Heart Association.
Read More
FDA approves gabapentin enacarbil for RLS
April 15th 2011FDA has approved gabapentin enacarbil (Horizant Extended-Release Tablets, GlaxoSmithKline and XenoPort), a once-daily treatment for moderate-to-severe restless legs syndrome, also known as Ekbom disease. It is the first medication in its class to be approved for this condition.
Read More
AHRQ report reveals increase in medication side effects and injuries
April 15th 2011The number of people treated in U.S. hospitals for illnesses and injuries from taking medicines increased 52%-from 1.2 million to 1.9 million-between 2004 and 2008, according to an April 2011 report from the Agency for Healthcare Research and Quality.
Read More
FDA approves Sylatron for injection for adjuvant treatment of melanoma
April 12th 2011FDA has approved peginterferon alfa-2b (Sylatron, Merck) for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy.
Read More
Rheumatic disease patients may require 2 doses of flu vaccine
April 8th 2011Patients with inflammatory rheumatic disease may need 2 doses of adjuvanted split influenza A vaccine to elicit the same antibody response as healthy individuals, reported a recent Swiss study published in Arthritis & Rheumatism.
Read More
Tiotropium superior to salmeterol in preventing exacerbations in COPD
April 8th 2011The anticholinergic drug tiotropium is more effective than the ?2-agonist salmeterol in preventing exacerbations in patients with moderate-to-very-severe chronic obstructive pulmonary disease, according to a multicenter European study published in the New England Journal of Medicine.
Read More
Suppressive therapy manages clopidogrel hypersensitivity
April 8th 2011Clopidogrel hypersensitivity, which affects 6% of patients, can be successfully treated using short-course corticosteroids and antihistamines without interrupting drug therapy, reported researchers at Jefferson Medical College in Philadelphia.
Read More
Combination of ACEI and ARB therapy increases renal risks in elderly
April 8th 2011Combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers is associated with increased risk of adverse renal outcomes, according to a recent study published in the Canadian Medical Association Journal.
Read More
High-dose clopidogrel does not reduce mortality after PCI
April 1st 2011The use of high-dose clopidogrel compared with use of standard-dose clopidogrel does not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis among patients with high on-treatment reactivity after percutaneous coronary intervention with drug-eluting stents, according to a recent multicenter study published in the Journal of the American Medical Association.
Read More
Vimovo well tolerated by arthritis patients at risk for gastric ulcers
April 1st 2011Naproxen/esomeprazole magnesium (Vimovo, AstraZeneca and Pozen) 500/20-mg delayed-release tablets was generally well tolerated in osteoarthritis patients requiring daily NSAID therapy who were at risk for NSAID-associated ulcers, according to an open-label, multicenter phase 3 study.
Read More
5α-reductase inhibitors in BPH linked with adverse sexual effects
April 1st 20115?-reductase inhibitors may cause persistent erectile dysfunction, depression, and loss of libido, even after discontinuing use, in men being treated for systems of benign prostatic hyperplasia and androgenetic alopecia, according to a literature review published in the March 2011 issue of The Journal of Sexual Medicine.
Read More